Ka Shing Cheung1,2, Lok Ka Lam1, Wai Kay Seto1,2, Wai K Leung1. 1. Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. 2. Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Abstract
BACKGROUND: Recent studies suggested that use of antibiotics may interfere with treatment responses to immune checkpoint inhibitors (ICIs). We determined whether concurrent use of antibiotics during ICI therapy was associated with adverse outcomes in patients with advanced hepatocellular carcinoma (HCC). METHODS: This is a territory-wide retrospective cohort study including all advanced HCC patients who received ICIs (nivolumab, pembrolizumab, or ipilimumab) between January 2014 and December 2019. Exclusion criteria included prior liver transplantation and use of cabozantinib, regorafenib, or ramucirumab. The exposure of interest was concurrent antibiotic use within 30 days before or after the commencement of ICI. The adjusted hazard ratio (aHR) of cancer-related mortality and all-cause mortality with antibiotic use was derived by propensity score (PS) matching in 1:2 ratio of covariates including baseline characteristics, causes of cirrhosis, Child-Pugh status, prior HCC treatment, comorbidities, concurrent medications, and laboratory results including alpha fetoprotein. RESULTS: A total of 395 HCC patients who had received ICIs were included. During a median follow-up of 16.5 months (interquartile range [IQR]: 5.6-44.3), there were 286 (72.4%) deaths including 231 cancer-related deaths. The median time from the first ICI to event was 7.7 months (IQR: 4.0-16.8). PS matching of 56 antibiotic users with 99 nonusers showed that concurrent antibiotic use with ICI was associated with higher cancer-related (aHR: 1.66; 95% CI: 1.08-2.54) and all-cause mortality (aHR: 1.63; 95% CI: 1.17-2.28). CONCLUSIONS: Concurrent antibiotic use during immunotherapy was associated with higher mortality in patients with advanced HCC. Further studies should examine the role of gut dysbiosis on responses to ICI.
BACKGROUND: Recent studies suggested that use of antibiotics may interfere with treatment responses to immune checkpoint inhibitors (ICIs). We determined whether concurrent use of antibiotics during ICI therapy was associated with adverse outcomes in patients with advanced hepatocellular carcinoma (HCC). METHODS: This is a territory-wide retrospective cohort study including all advanced HCC patients who received ICIs (nivolumab, pembrolizumab, or ipilimumab) between January 2014 and December 2019. Exclusion criteria included prior liver transplantation and use of cabozantinib, regorafenib, or ramucirumab. The exposure of interest was concurrent antibiotic use within 30 days before or after the commencement of ICI. The adjusted hazard ratio (aHR) of cancer-related mortality and all-cause mortality with antibiotic use was derived by propensity score (PS) matching in 1:2 ratio of covariates including baseline characteristics, causes of cirrhosis, Child-Pugh status, prior HCC treatment, comorbidities, concurrent medications, and laboratory results including alpha fetoprotein. RESULTS: A total of 395 HCC patients who had received ICIs were included. During a median follow-up of 16.5 months (interquartile range [IQR]: 5.6-44.3), there were 286 (72.4%) deaths including 231 cancer-related deaths. The median time from the first ICI to event was 7.7 months (IQR: 4.0-16.8). PS matching of 56 antibiotic users with 99 nonusers showed that concurrent antibiotic use with ICI was associated with higher cancer-related (aHR: 1.66; 95% CI: 1.08-2.54) and all-cause mortality (aHR: 1.63; 95% CI: 1.17-2.28). CONCLUSIONS: Concurrent antibiotic use during immunotherapy was associated with higher mortality in patients with advanced HCC. Further studies should examine the role of gut dysbiosis on responses to ICI.
Authors: Ka Shing Cheung; Esther W Chan; Lijia Chen; Wai Kay Seto; Ian C K Wong; Wai K Leung Journal: Diabetes Care Date: 2019-07-11 Impact factor: 19.112
Authors: V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo Journal: Science Date: 2017-11-02 Impact factor: 47.728
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: L Derosa; M D Hellmann; M Spaziano; D Halpenny; M Fidelle; H Rizvi; N Long; A J Plodkowski; K C Arbour; J E Chaft; J A Rouche; L Zitvogel; G Zalcman; L Albiges; B Escudier; B Routy Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: Howard Lim; Ravi Ramjeesingh; Dave Liu; Vincent C Tam; Jennifer J Knox; Paul B Card; Brandon M Meyers Journal: J Natl Cancer Inst Date: 2021-02-01 Impact factor: 13.506
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Ka Shing Cheung; Esther W Chan; Anthony Tam; Irene O L Wong; Wai Kay Seto; Ivan F N Hung; Ian C K Wong; Wai K Leung Journal: Cancer Med Date: 2022-04-29 Impact factor: 4.711